BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC Med 2018;16:34. [PMID: 29510692 DOI: 10.1186/s12916-018-1016-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 157] [Article Influence: 37.5] [Reference Citation Analysis]
Number Citing Articles
1 Rosenberg GA. Clinical aspects of diagnosis in dementia. Neuroinflammation in Vascular Dementia 2023. [DOI: 10.1016/b978-0-12-823455-6.00009-2] [Reference Citation Analysis]
2 Agbomi LL, Onuoha CP, Nathaniel SI, Coker-ayo OO, Bailey-taylor MJ, Roley LT, Poupore N, Goodwin RL, Nathaniel TI. Gender differences in Parkinson's disease with dementia and dementia with Lewy bodies. Aging and Health Research 2022;2:100096. [DOI: 10.1016/j.ahr.2022.100096] [Reference Citation Analysis]
3 Ryman S, Vakhtin AA, Richardson SP, Lin HC. Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases. J Neurol 2022. [DOI: 10.1007/s00415-022-11461-9] [Reference Citation Analysis]
4 Ojo AB, Gyebi GA, Alabi O, Iyobhebhe M, Kayode AB, Nwonuma CO, Ojo OA. Syzygium aromaticum (L.) Merr. & L.M.Perry mitigates iron-mediated oxidative brain injury via in vitro, ex vivo, and in silico approaches. Journal of Molecular Structure 2022;1268:133675. [DOI: 10.1016/j.molstruc.2022.133675] [Reference Citation Analysis]
5 Seebaluck J, Colebatch JG, Chan BS. Butyrophenone‐induced neuroleptic malignant syndrome in Lewy body dementia: A cautionary tale. Emerg Medicine Australasia 2022. [DOI: 10.1111/1742-6723.14113] [Reference Citation Analysis]
6 Fei M, Wang F, Wu H, Liu S, Gan J, Ji Y. Characteristics of initial symptoms in patients with dementia with Lewy body disease. Front Neurol 2022;13:1024995. [DOI: 10.3389/fneur.2022.1024995] [Reference Citation Analysis]
7 Li M, Fan Y, Li Q, Wang X, Zhao L, Zhu M, Schroder N. Liquid-Liquid Phase Separation Promotes Protein Aggregation and Its Implications in Ferroptosis in Parkinson’s Disease Dementia. Oxidative Medicine and Cellular Longevity 2022;2022:1-13. [DOI: 10.1155/2022/7165387] [Reference Citation Analysis]
8 Mehta RI, Schneider JA. Neuropathology of the Common Forms of Dementia. Clinics in Geriatric Medicine 2022. [DOI: 10.1016/j.cger.2022.07.005] [Reference Citation Analysis]
9 Zhang S, Ma Y. Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms. World J Psychiatry 2022; 12(9): 1127-1140 [DOI: 10.5498/wjp.v12.i9.1127] [Reference Citation Analysis]
10 Kong L, Xi J, Jiang Z, Yu X, Liu H, Wang Z, Agrawal N. Zonisamide’s Efficacy and Safety on Parkinson’s Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/4817488] [Reference Citation Analysis]
11 Liebermann-jordanidis H, Roheger M, Boosfeld L, Franklin J, Kalbe E. Which Test Is the Best to Assess Visuo-Cognitive Impairment in Patients with Parkinson’s Disease with Mild Cognitive Impairment and Dementia? A Systematic Review and Meta-Analysis. JPD 2022;12:1749-1782. [DOI: 10.3233/jpd-223238] [Reference Citation Analysis]
12 Levy G, Levin B, Engelhardt E. Advancing the Genetics of Lewy Body Disorders with Disease‐Modifying Treatments in Mind. Advanced Genetics 2022. [DOI: 10.1002/ggn2.202200011] [Reference Citation Analysis]
13 Jennings JL, Peraza LR, Baker M, Alter K, Taylor J, Bauer R. Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis. Alz Res Therapy 2022;14:109. [DOI: 10.1186/s13195-022-01046-z] [Reference Citation Analysis]
14 Oyanagi K, Hayashi H, Yamada M, Kakita A. The large neuron involvement in the neostriatum in Lewy body diseases. Neuropathology 2022. [PMID: 35860863 DOI: 10.1111/neup.12819] [Reference Citation Analysis]
15 Lu J, Ge J, Chen K, Sun Y, Liu F, Yu H, Xu Q, Li L, Ju Z, Lin H, Guan Y, Guo Q, Wang J, Zuo C, Wu P. Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias. Mov Disord 2022. [PMID: 35857319 DOI: 10.1002/mds.29138] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Jellinger KA. Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies? Parkinsonism Relat Disord 2022;100:24-32. [PMID: 35691178 DOI: 10.1016/j.parkreldis.2022.05.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wong YY, Wu CY, Yu D, Kim E, Wong M, Elez R, Zebarth J, Ouk M, Tan J, Liao J, Haydarian E, Li S, Fang Y, Li P, Pakosh M, Tartaglia MC, Masellis M, Swardfager W. Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis. Parkinsonism Relat Disord 2022:S1353-8020(22)00187-0. [PMID: 35760718 DOI: 10.1016/j.parkreldis.2022.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jellinger KA. Morphological basis of Parkinson disease-associated cognitive impairment: an update. J Neural Transm (Vienna) 2022. [PMID: 35726096 DOI: 10.1007/s00702-022-02522-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Gan J, Liu S, Chen Z, Yang Y, Ma L, Meng Q, Wang XD, Liu C, Li X, Zhang W, Ji Y. Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies. J Alzheimers Dis 2022;1:1-12. [PMID: 35723094 DOI: 10.3233/JAD-220082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Landry IS, Aluri J, Schuck E, Ino M, Horie K, Boyd P, Reyderman L, Lai R. Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial. Alzheimer Dis Assoc Disord 2022. [PMID: 35700341 DOI: 10.1097/WAD.0000000000000515] [Reference Citation Analysis]
21 Prasad S, Katta MR, Abhishek S, Sridhar R, Valisekka SS, Hameed M, Kaur J, Walia N. Recent advances in Lewy body dementia: A comprehensive review. Dis Mon 2022;:101441. [PMID: 35690493 DOI: 10.1016/j.disamonth.2022.101441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li H, Mirabel R, Zimmerman J, Ghiviriga I, Phidd DK, Horenstein N, Urs NM. Structure-Functional Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward the Discovery of Biased Dopamine D1 Receptor Agonists. ACS Chem Neurosci 2022. [PMID: 35658399 DOI: 10.1021/acschemneuro.2c00235] [Reference Citation Analysis]
23 Ren Y, Wang Q, Yang Z, Feng L, Zhang Y. MCC950 ameliorates the dementia symptom at the early age of line M83 mouse and reduces hippocampal α-synuclein accumulation. Biochemical and Biophysical Research Communications 2022;611:23-30. [DOI: 10.1016/j.bbrc.2022.04.076] [Reference Citation Analysis]
24 Schalkamp AK, Rahman N, Monzón-Sandoval J, Sandor C. Deep phenotyping for precision medicine in Parkinson's disease. Dis Model Mech 2022;15:dmm049376. [PMID: 35647913 DOI: 10.1242/dmm.049376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Just MK, Gram H, Theologidis V, Jensen PH, Nilsson KPR, Lindgren M, Knudsen K, Borghammer P, Van Den Berge N. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies. Front Aging Neurosci 2022;14:907293. [DOI: 10.3389/fnagi.2022.907293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
26 Emdina A, Hermann P, Varges D, Nuhn S, Goebel S, Bunck T, Maass F, Schmitz M, Llorens F, Kruse N, Lingor P, Mollenhauer B, Zerr I. Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline. Diagnostics 2022;12:1259. [DOI: 10.3390/diagnostics12051259] [Reference Citation Analysis]
27 Jensen KH, Stalder AK, Wernersson R, Roloff-handschin T, Hansen DH, Groenen PMA. A molecular view of amyotrophic lateral sclerosis through the lens of interaction network modules. PLoS ONE 2022;17:e0268159. [DOI: 10.1371/journal.pone.0268159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Kozubek M, Hoenke S, Schmidt T, Ströhl D, Csuk R. Platanic acid derived amides are more cytotoxic than their corresponding oximes. Med Chem Res. [DOI: 10.1007/s00044-022-02902-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Borda MG, Jaramillo‐jimenez A, Giil LM, Tovar‐rios DA, Soennesyn H, Aarsland D. Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.590] [Reference Citation Analysis]
30 Shkodina AD, Tarianyk KA, Boiko DI, Zehravi M, Akter S, Md Ashraf G, Rahman H. Cognitive and affective disturbances in patients with Parkinson's disease: perspectives for classifying of motor/neuropsychiatric subtypes. Neuroscience Letters 2022. [DOI: 10.1016/j.neulet.2022.136675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Foska A, Tsantzali I, Sideri E, Stefanou MI, Bakola E, Kitsos DK, Zompola C, Bonakis A, Giannopoulos S, Voumvourakis KI, Tsivgoulis G, Paraskevas GP. Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies. Medicina 2022;58:612. [DOI: 10.3390/medicina58050612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 . Introduction. Non-Motor Parkinson's Disease 2022. [DOI: 10.1017/9781009039291.001] [Reference Citation Analysis]
33 Korczyn AD. Mild Cognitive Impairment. Non-Motor Parkinson's Disease 2022. [DOI: 10.1017/9781009039291.007] [Reference Citation Analysis]
34 Jellinger KA. Heterogeneity of Multiple System Atrophy: An Update. Biomedicines 2022;10:599. [DOI: 10.3390/biomedicines10030599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Panda SP, Soni U. A review of dementia, focusing on the distinct roles of viral protein corona and MMP9 in dementia: Potential pharmacotherapeutic priorities. Ageing Res Rev 2022;75:101560. [PMID: 35031512 DOI: 10.1016/j.arr.2022.101560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Falade AO, Adewole KE, Ishola AA, Gyebi GA, Olajide NR. Computational studies on the cholinesterase, beta-secretase 1 (BACE1) and monoamine oxidase (MAO) inhibitory activities of endophytes-derived compounds: towards discovery of novel neurotherapeutics. J Biomol Struct Dyn 2022;:1-15. [PMID: 35118932 DOI: 10.1080/07391102.2022.2035255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang Y, Huang C, Guo Q, Chu H. Aquaporin-4 and Cognitive Disorders. Aging Dis 2022;13:61-72. [PMID: 35111362 DOI: 10.14336/AD.2021.0731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 D’antonio F, Boccia M, Di Vita A, Suppa A, Fabbrini A, Canevelli M, Caramia F, Fiorelli M, Guariglia C, Ferracuti S, de Lena C, Aarsland D, ffytche D. Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology. J Neurol. [DOI: 10.1007/s00415-022-10983-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 刘 一. Neuropsychological Profile of Different Types of Dementia Due to Different Diseases. ACM 2022;12:593-598. [DOI: 10.12677/acm.2022.121088] [Reference Citation Analysis]
40 Mordhorst S, Coulehan K, Roseman EC. Neuropsychology Assessment in Dementia and Neurodegenerative Disease. Hybrid PET/MR Neuroimaging 2022. [DOI: 10.1007/978-3-030-82367-2_21] [Reference Citation Analysis]
41 Bhargava S, Jain I, Singh M, Rachana. Music Therapy in Dementia. Current Thoughts on Dementia 2022. [DOI: 10.1007/978-981-16-7606-2_18] [Reference Citation Analysis]
42 Wakasugi N, Hanakawa T. It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer's and Lewy Body Disease Spectra. Front Syst Neurosci 2021;15:777706. [PMID: 34867224 DOI: 10.3389/fnsys.2021.777706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Chiu SY, Bowers D, Armstrong MJ. Lewy Body Dementias: Controversies and Drug Development. Neurotherapeutics 2021. [PMID: 34859379 DOI: 10.1007/s13311-021-01161-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Biglan K, Munsie L, Svensson KA, Ardayfio P, Pugh M, Sims J, Brys M. Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial. Mov Disord 2021. [PMID: 34859493 DOI: 10.1002/mds.28879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Kurzawa-Akanbi M, Tammireddy S, Fabrik I, Gliaudelytė L, Doherty MK, Heap R, Matečko-Burmann I, Burmann BM, Trost M, Lucocq JM, Gherman AV, Fairfoul G, Singh P, Burté F, Green A, McKeith IG, Härtlova A, Whitfield PD, Morris CM. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathol 2021;142:961-84. [PMID: 34514546 DOI: 10.1007/s00401-021-02367-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
46 Simon C, Soga T, Okano HJ, Parhar I. α-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. Cell Biosci 2021;11:196. [PMID: 34798911 DOI: 10.1186/s13578-021-00709-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Scholefield M, Church SJ, Xu J, Patassini S, Roncaroli F, Hooper NM, Unwin RD, Cooper GJS. Severe and Regionally Widespread Increases in Tissue Urea in the Human Brain Represent a Novel Finding of Pathogenic Potential in Parkinson's Disease Dementia. Front Mol Neurosci 2021;14:711396. [PMID: 34751215 DOI: 10.3389/fnmol.2021.711396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ouchani M, Gharibzadeh S, Jamshidi M, Amini M. A Review of Methods of Diagnosis and Complexity Analysis of Alzheimer's Disease Using EEG Signals. Biomed Res Int 2021;2021:5425569. [PMID: 34746303 DOI: 10.1155/2021/5425569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zhang G, Liu S, Chen Z, Shi Z, Hu W, Ma L, Wang X, Li X, Ji Y. Association of Elevated Plasma Total Homocysteine With Dementia With Lewy Bodies: A Case-Control Study. Front Aging Neurosci 2021;13:724990. [PMID: 34720990 DOI: 10.3389/fnagi.2021.724990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Han J, Fan Y, Wu P, Huang Z, Li X, Zhao L, Ji Y, Zhu M. Parkinson's Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron. Front Aging Neurosci 2021;13:743754. [PMID: 34707492 DOI: 10.3389/fnagi.2021.743754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
51 Riederer P, Monoranu C, Strobel S, Iordache T, Sian-Hülsmann J. Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease. J Neural Transm (Vienna) 2021;128:1577-98. [PMID: 34636961 DOI: 10.1007/s00702-021-02414-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
52 Palermo G, Belli E, Tommasini L, Morganti R, Frosini D, Nicoletti V, Tognoni G, Siciliano G, Bonuccelli U, Baldacci F, Ceravolo R. Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. J Alzheimers Dis 2021;84:757-66. [PMID: 34602466 DOI: 10.3233/JAD-210006] [Reference Citation Analysis]
53 Li H, Mirabel R, Zimmerman J, Ghiviriga I, Phidd DK, Horenstein N, Urs NM. Structure-Functional-Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward Discovery of Biased D1 Agonists.. [DOI: 10.1101/2021.10.01.462758] [Reference Citation Analysis]
54 Lee YH, Jeon S, Yoo HS, Chung SJ, Jung JH, Baik K, Sohn YH, Lee PH, Yun M, Evans AC, Ye BS. Effect of Alzheimer's Disease and Lewy Body Disease on Metabolic Changes. J Alzheimers Dis 2021;79:1471-87. [PMID: 33459638 DOI: 10.3233/JAD-201094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Feleke R, Reynolds RH, Smith AM, Tilley B, Taliun SAG, Hardy J, Matthews PM, Gentleman S, Owen DR, Johnson MR, Srivastava PK, Ryten M. Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. Acta Neuropathol 2021;142:449-74. [PMID: 34309761 DOI: 10.1007/s00401-021-02343-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
56 Bono AD, Twaite JT, Krch D, McCabe DL, Scorpio KA, Stafford RJ, Borod JC. Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. Handb Clin Neurol 2021;183:175-96. [PMID: 34389117 DOI: 10.1016/B978-0-12-822290-4.00015-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Wilson H, de Natale ER, Politis M. Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. Handb Clin Neurol 2021;179:189-205. [PMID: 34225962 DOI: 10.1016/B978-0-12-819975-6.00010-8] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
58 Bollipo LM, K V K. Fast and robust supervised machine learning approach for classification and prediction of Parkinson’s disease onset. Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization 2021;9:690-706. [DOI: 10.1080/21681163.2021.1941262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Manzanza NO, Sedlackova L, Kalaria RN. Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders. Front Aging Neurosci 2021;13:690293. [PMID: 34248606 DOI: 10.3389/fnagi.2021.690293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
60 Milán-Tomás Á, Fernández-Matarrubia M, Rodríguez-Oroz MC. Lewy Body Dementias: A Coin with Two Sides? Behav Sci (Basel) 2021;11:94. [PMID: 34206456 DOI: 10.3390/bs11070094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Stoyka LE, Mahoney CL, Thrasher DR, Russell DL, Cook AK, Harris AT, Narayanan A, Janado TP, Standaert DG, Roberson ED, Volpicelli-Daley LA. Templated α-Synuclein Inclusion Formation Is Independent of Endogenous Tau. eNeuro 2021;8:ENEURO. [PMID: 33972291 DOI: 10.1523/ENEURO.0458-20.2021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
62 Motyl JA, Strosznajder JB, Wencel A, Strosznajder RP. Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease. Int J Mol Sci 2021;22:6277. [PMID: 34207975 DOI: 10.3390/ijms22126277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
63 Politis A, Kokras N, Souvatzoglou M, Siarkos K, Toulas P, Potagas C, Hatzipanagiotou T, Limouris G, Alexopoulos P. Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series. BMC Psychiatry 2021;21:289. [PMID: 34082747 DOI: 10.1186/s12888-021-03298-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Luukkainen L, Huttula S, Väyrynen H, Helisalmi S, Kytövuori L, Haapasalo A, Hiltunen M, Remes AM, Krüger J. Mutation Analysis of the Genes Associated with Parkinson's Disease in a Finnish Cohort of Early-Onset Dementia. J Alzheimers Dis 2020;76:955-65. [PMID: 32568194 DOI: 10.3233/JAD-200069] [Reference Citation Analysis]
65 Candelise N, Scaricamazza S, Salvatori I, Ferri A, Valle C, Manganelli V, Garofalo T, Sorice M, Misasi R. Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications. Int J Mol Sci 2021;22:6016. [PMID: 34199513 DOI: 10.3390/ijms22116016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
66 Erskine D, Attems J. Insights into Lewy body disease from rare neurometabolic disorders. J Neural Transm (Vienna) 2021. [PMID: 34056672 DOI: 10.1007/s00702-021-02355-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, Srinivasan A, Pellegrino C, Kannan A, Bolla SR, Chidambaram SB, Sakharkar MK. "Janus-Faced" α-Synuclein: Role in Parkinson's Disease. Front Cell Dev Biol 2021;9:673395. [PMID: 34124057 DOI: 10.3389/fcell.2021.673395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Cozma L, Avasilichioaei M, Dima N, Popescu BO. Of Criteria and Men-Diagnosing Atypical Parkinsonism: Towards an Algorithmic Approach. Brain Sci 2021;11:695. [PMID: 34070571 DOI: 10.3390/brainsci11060695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Liang YT, Lin CY, Wang YH, Chou HH, Wei JC. Associations of Chinese Herbal Medicine Usage with Risk of Dementia in Patients with Parkinson's Disease: A Population-Based, Nested Case-Control Study. J Altern Complement Med 2021;27:606-12. [PMID: 33979532 DOI: 10.1089/acm.2020.0422] [Reference Citation Analysis]
70 Scamarcia PG, Agosta F, Caso F, Filippi M. Update on neuroimaging in non-Alzheimer's disease dementia: a focus on the Lewy body disease spectrum. Curr Opin Neurol 2021;34:532-8. [PMID: 34227573 DOI: 10.1097/WCO.0000000000000958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
71 Giil LM, Aarsland D. Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. J Alzheimers Dis 2020;73:1321-30. [PMID: 31903991 DOI: 10.3233/JAD-190731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
72 Jellinger KA. Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. J Neural Transm (Vienna) 2021;128:687-99. [PMID: 33928445 DOI: 10.1007/s00702-021-02345-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
73 Feleke R, Reynolds RH, Smith A, Tilley B, Gagliano Taliun SA, Hardy J, Matthews PM, Gentleman S, Owen D, Johnson MR, Srivastava P, Ryten M. Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy Body diseases.. [DOI: 10.1101/2021.04.22.440800] [Reference Citation Analysis]
74 Uddin MS, Sumsuzzman DM, Jeandet P, Behl T, Rauf A, Amran MS, Ashraf GM. Deciphering the Interacting Mechanisms of Circadian Disruption and Alzheimer's Disease. Neurochem Res 2021;46:1603-17. [PMID: 33871799 DOI: 10.1007/s11064-021-03325-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
75 Erskine D, Koss D, Korolchuk VI, Outeiro TF, Attems J, McKeith I. Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathol 2021;141:511-26. [PMID: 33515275 DOI: 10.1007/s00401-021-02266-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
76 Gan J, Liu S, Wang X, Shi Z, Shen L, Li X, Guo Q, Yuan J, Zhang N, You Y, Lv Y, Zheng D, Ji Y; China Lewy Body Disease Collaborative Alliance. Clinical characteristics of Lewy body dementia in Chinese memory clinics. BMC Neurol 2021;21:144. [PMID: 33789600 DOI: 10.1186/s12883-021-02169-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
77 Huq AJ, Sexton A, Lacaze P, Masters CL, Storey E, Velakoulis D, James PA, Winship IM. Genetic testing in dementia-A medical genetics perspective. Int J Geriatr Psychiatry 2021;36:1158-70. [PMID: 33779003 DOI: 10.1002/gps.5535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Jellinger KA. Morphological differences between dementia with Lewy bodies and Parkinson's disease-dementia. Neuropathol Appl Neurobiol 2021. [PMID: 33735473 DOI: 10.1111/nan.12708] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
79 Chalkias E, Topouzis F, Tegos T, Tsolaki M. The Contribution of Ocular Biomarkers in the Differential Diagnosis of Alzheimer's Disease versus Other Types of Dementia and Future Prospects. J Alzheimers Dis 2021;80:493-504. [PMID: 33554918 DOI: 10.3233/JAD-201516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Jellinger KA. Different patterns of hippocampal subfield pathology in Lewy body disease and Alzheimer's disease. Neuropathol Appl Neurobiol 2021;47:705-6. [PMID: 33471382 DOI: 10.1111/nan.12695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Segers K, Benoit F, Meyts JM, Glibert G, Levy S, Surquin M. Dementia with Lewy bodies in first-generation immigrants in a European memory clinic. Acta Neurol Belg 2021;121:219-23. [PMID: 32931000 DOI: 10.1007/s13760-020-01492-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Orad RI, Shiner T. Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities. J Neurol 2021. [PMID: 33511432 DOI: 10.1007/s00415-021-10402-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
83 Papuć E. Dementia with Lewy bodies and Parkinson’s disease dementia-two independent disorders or one clinical entity within a clinical spectrum of synucleinopathies? Current Problems of Psychiatry 2020;21:161-6. [DOI: 10.2478/cpp-2020-0015] [Reference Citation Analysis]
84 Villemagne VL, Barkhof F, Garibotto V, Landau SM, Nordberg A, van Berckel BNM. Molecular Imaging Approaches in Dementia. Radiology 2021;298:517-30. [PMID: 33464184 DOI: 10.1148/radiol.2020200028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
85 Li X, Ye M, Wang Y, Qiu M, Fu T, Zhang J, Zhou B, Lu S. How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study. Phys Chem Chem Phys 2020;22:20421-33. [PMID: 32914822 DOI: 10.1039/d0cp03171b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
86 Jung J, Bae SH, Han JH, Kwak SH, Nam GS, Lee PH, Sohn YH, Yun M, Ye BS. Relationship between Hearing Loss and Dementia Differs According to the Underlying Mechanism. J Clin Neurol 2021;17:290-9. [PMID: 33835751 DOI: 10.3988/jcn.2021.17.2.290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Segura-aguilar J. Parkinson's disease. Clinical Studies and Therapies in Parkinson's Disease 2021. [DOI: 10.1016/b978-0-12-822120-4.00001-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Murphy C. Olfactory Impairment and Neurodegenerative Disorders. Sensory Science and Chronic Diseases 2021. [DOI: 10.1007/978-3-030-86282-4_7] [Reference Citation Analysis]
89 Sengoku R. Neuropathological features of cognitive decline in Lewy body dementia. Neurology & Clinical Neurosc 2020;8:356-361. [DOI: 10.1111/ncn3.12444] [Reference Citation Analysis]
90 Low CYB, Lee JH, Lim FTW, Lee C, Ballard C, Francis PT, Lai MKP, Tan MGK. Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. Brain Pathol 2021;31:253-66. [PMID: 33128789 DOI: 10.1111/bpa.12917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
91 Saeed U, Lang AE, Masellis M. Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. Front Neurol 2020;11:572976. [PMID: 33178113 DOI: 10.3389/fneur.2020.572976] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
92 Panza F, Lozupone M, Watling M, Imbimbo BP. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. Expert Opin Pharmacother 2021;22:325-37. [PMID: 33021110 DOI: 10.1080/14656566.2020.1828350] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Alosco ML, Cherry JD, Huber BR, Tripodis Y, Baucom Z, Kowall NW, Saltiel N, Goldstein LE, Katz DI, Dwyer B, Daneshvar DH, Palmisano JN, Martin B, Cantu RC, Stern RA, Alvarez VE, Mez J, Stein TD, McKee AC. Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme. Acta Neuropathol 2020;140:495-512. [PMID: 32778942 DOI: 10.1007/s00401-020-02197-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
94 Coughlin DG, Ittyerah R, Peterson C, Phillips JS, Miller S, Rascovsky K, Weintraub D, Siderowf AD, Duda JE, Hurtig HI, Wolk DA, McMillan CT, Yushkevich PA, Grossman M, Lee EB, Trojanowski JQ, Irwin DJ. Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease. Neuropathol Appl Neurobiol 2020;46:707-21. [PMID: 32892355 DOI: 10.1111/nan.12659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
95 Levy G, Levin B, Engelhardt E. The Nosology of Lewy Body Disorders From Analytic-Epidemiologic and Statistical Vantage Points. Mov Disord 2020;35:2156-61. [PMID: 32936973 DOI: 10.1002/mds.28288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
96 Shang S, Chen YC, Zhang H, Dou W, Qian L, Yin X, Wu J. Mapping the Interactive Effects of ApoE Gene Polymorphism on Caudate Functional Connectivity in Mild Cognitive Impairment Associated With Parkinson's Disease. Front Neurosci 2020;14:857. [PMID: 33041748 DOI: 10.3389/fnins.2020.00857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Davis-Fantauzzi A. The Rise of Dementia With Lewy Bodies: Nursing Interventions and Implications. J Neurosci Nurs 2020;52:311-5. [PMID: 32925559 DOI: 10.1097/JNN.0000000000000540] [Reference Citation Analysis]
98 Pennington C, Duncan G, Ritchie C. Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review. Int J Geriatr Psychiatry 2021;36:15-30. [PMID: 32869379 DOI: 10.1002/gps.5415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
99 Chatterjee M, van Steenoven I, Huisman E, Oosterveld L, Berendse H, van der Flier WM, Del Campo M, Lemstra AW, van de Berg WDJ, Teunissen CE. Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. Biomolecules 2020;10:E1177. [PMID: 32806791 DOI: 10.3390/biom10081177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Urbizu A, Beyer K. Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. Int J Mol Sci 2020;21:E4718. [PMID: 32630630 DOI: 10.3390/ijms21134718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
101 Raval U, Harary JM, Zeng E, Pasinetti GM. The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders. Expert Rev Neurother 2020;20:673-86. [PMID: 32459513 DOI: 10.1080/14737175.2020.1775585] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
102 Palermo G, Del Prete E, Bonuccelli U, Ceravolo R. Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies. J Neurol 2020;267:3444-56. [PMID: 32594302 DOI: 10.1007/s00415-020-09985-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
103 Ferman TJ, Aoki N, Boeve BF, Aakre JA, Kantarci K, Graff-Radford J, Parisi JE, Van Gerpen JA, Graff-Radford NR, Uitti RJ, Pedraza O, Murray ME, Wszolek ZK, Reichard RR, Fields JA, Ross OA, Knopman DS, Petersen RC, Dickson DW. Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution. Neurology 2020;95:e155-65. [PMID: 32561678 DOI: 10.1212/WNL.0000000000009763] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
104 Surendranathan A, Kane JPM, Bentley A, Barker SAH, Taylor JP, Thomas AJ, Allan LM, McNally RJ, James PW, McKeith IG, Burn DJ, O'Brien JT. Clinical diagnosis of Lewy body dementia. BJPsych Open 2020;6:e61. [PMID: 32539875 DOI: 10.1192/bjo.2020.44] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
105 Avdeeva NV. Novel mGluR4 agonist Rapitalam ameliorates motor dysfunction in mice with tau-associated neurodegeneration. RRP 2020;6:9-17. [DOI: 10.3897/rrpharmacology.6.52098] [Reference Citation Analysis]
106 Hommel ALAJ, Meinders MJ, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, Laurens B, Spampinato U, Meissner W, Rosqvist K, Timpka J, Odin P, Wittenberg M, Bloem PhD BR, Koopmans RT, Schrag A; Care of Late‐Stage Parkinsonism Consortium. The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. Mov Disord Clin Pract 2020;7:531-42. [PMID: 32626798 DOI: 10.1002/mdc3.12968] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
107 Green H, Tsitsi P, Markaki I, Aarsland D, Svenningsson P. Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways. CNS Drugs. 2019;33:143-160. [PMID: 30687888 DOI: 10.1007/s40263-018-0601-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
108 Thompson C, Otero P, Srinageshwar B, Petersen RB, Dunbar GL, Rossignol J. Possible roles of epigenetics in stem cell therapy for Parkinson's disease. Epigenomics 2020;12:647-56. [PMID: 32396465 DOI: 10.2217/epi-2019-0347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
109 Chouliaras L, Kumar GS, Thomas AJ, Lunnon K, Chinnery PF, O'Brien JT. Epigenetic regulation in the pathophysiology of Lewy body dementia. Prog Neurobiol 2020;192:101822. [PMID: 32407744 DOI: 10.1016/j.pneurobio.2020.101822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
110 Schumacher J, Thomas AJ, Taylor JP. Dynamic functional connectivity changes in Lewy body disease.Brain. 2019;142:e68. [PMID: 31605477 DOI: 10.1093/brain/awz315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Jellinger KA. Neuropathological findings in multiple system atrophy with cognitive impairment. J Neural Transm (Vienna) 2020;127:1031-9. [PMID: 32367182 DOI: 10.1007/s00702-020-02201-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
112 Uemura N, Uemura MT, Luk KC, Lee VM, Trojanowski JQ. Cell-to-Cell Transmission of Tau and α-Synuclein. Trends Mol Med 2020;26:936-52. [PMID: 32371172 DOI: 10.1016/j.molmed.2020.03.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 27.5] [Reference Citation Analysis]
113 Lashuel HA. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Neurobiol Dis 2020;141:104876. [PMID: 32339655 DOI: 10.1016/j.nbd.2020.104876] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 25.0] [Reference Citation Analysis]
114 Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2020;94:e2076-87. [PMID: 32332125 DOI: 10.1212/WNL.0000000000009434] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
115 Tanaka M, Toldi J, Vécsei L. Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. Int J Mol Sci 2020;21:E2431. [PMID: 32244523 DOI: 10.3390/ijms21072431] [Cited by in Crossref: 93] [Cited by in F6Publishing: 99] [Article Influence: 46.5] [Reference Citation Analysis]
116 Morgan SA, Lavenir I, Fan J, Masuda-Suzukake M, Passarella D, DeTure MA, Dickson DW, Ghetti B, Goedert M. α-Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species. J Biol Chem 2020;295:6652-64. [PMID: 32209651 DOI: 10.1074/jbc.RA119.012179] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
117 Yoo HS, Lee S, Chung SJ, Lee YH, Lee PH, Sohn YH, Lee S, Yun M, Ye BS. Dopaminergic Depletion, β-Amyloid Burden, and Cognition in Lewy Body Disease. Ann Neurol 2020;87:739-50. [PMID: 32078179 DOI: 10.1002/ana.25707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
118 Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiol Dis 2020;137:104782. [PMID: 31991247 DOI: 10.1016/j.nbd.2020.104782] [Cited by in Crossref: 145] [Cited by in F6Publishing: 153] [Article Influence: 72.5] [Reference Citation Analysis]
119 Kovacs GG. Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases? Curr Opin Neurol 2019;32:279-91. [PMID: 30672825 DOI: 10.1097/WCO.0000000000000664] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
120 Ciafone J, Little B, Thomas AJ, Gallagher P. The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias. J Int Neuropsychol Soc 2020;26:210-25. [PMID: 31826772 DOI: 10.1017/S1355617719001103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
121 Agnihotri A, Aruoma OI. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals. Journal of the American College of Nutrition 2020;39:16-27. [DOI: 10.1080/07315724.2019.1683379] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
122 Vatter S, Leroi I. Long-Term Partnerships in Lewy Body Dementias. Geriatric Medicine and Gerontology 2019. [DOI: 10.5772/intechopen.86204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Nazarko L. Lewy body dementia: diagnosis, treatment and medical management. British Journal of Neuroscience Nursing 2019;15:277-84. [DOI: 10.12968/bjnn.2019.15.6.277] [Reference Citation Analysis]
124 Segers K, Benoit F, Meyts J, Surquin M. Anxiety symptoms are quantitatively and qualitatively different in dementia with Lewy bodies than in Alzheimerʼs disease in the years preceding clinical diagnosis. Psychogeriatrics 2020;20:242-6. [DOI: 10.1111/psyg.12490] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
125 Trošt M, Perovnik M, Pirtošek Z. Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α-Synucleinopathies. Front Neurol 2019;10:1204. [PMID: 31798525 DOI: 10.3389/fneur.2019.01204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
126 Coughlin DG, Hurtig HI, Irwin DJ. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. Mov Disord 2020;35:5-19. [PMID: 31660655 DOI: 10.1002/mds.27867] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
127 Matar E, Shine JM, Halliday GM, Lewis SJG. Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain 2020;143:31-46. [DOI: 10.1093/brain/awz311] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
128 Nazarko L. Dementia 4. Lewy body dementia: diagnosis, treatment and medical management. British Journal of Healthcare Assistants 2019;13:474-81. [DOI: 10.12968/bjha.2019.13.10.474] [Reference Citation Analysis]
129 Singh B, Covelo A, Martell-Martínez H, Nanclares C, Sherman MA, Okematti E, Meints J, Teravskis PJ, Gallardo C, Savonenko AV, Benneyworth MA, Lesné SE, Liao D, Araque A, Lee MK. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy. Acta Neuropathol 2019;138:551-74. [PMID: 31168644 DOI: 10.1007/s00401-019-02032-w] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
130 Mc Ardle R, Galna B, Donaghy P, Thomas A, Rochester L. Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait? Alzheimer's & Dementia 2019;15:1367-77. [DOI: 10.1016/j.jalz.2019.06.4953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
131 Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron 2019;101:820-38. [PMID: 30844401 DOI: 10.1016/j.neuron.2019.01.056] [Cited by in Crossref: 213] [Cited by in F6Publishing: 171] [Article Influence: 71.0] [Reference Citation Analysis]
132 Vitanova KS, Stringer KM, Benitez DP, Brenton J, Cummings DM. Dementia associated with disorders of the basal ganglia. J Neurosci Res 2019;97:1728-41. [PMID: 31392765 DOI: 10.1002/jnr.24508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
133 Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, Kapaki E. In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies. Dement Geriatr Cogn Disord 2019;47:289-96. [PMID: 31311013 DOI: 10.1159/000500567] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
134 Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Castaño-Díez D, Schweighauser G, Graff-Meyer A, Goldie KN, Sütterlin R, Huisman E, Ingrassia A, Gier Y, Rozemuller AJM, Wang J, Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Großerüschkamp F, Niedieker D, El-Mashtoly SF, Quadri M, Van IJcken WFJ, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, Van de Berg WDJ, Lauer ME. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat Neurosci 2019;22:1099-109. [PMID: 31235907 DOI: 10.1038/s41593-019-0423-2] [Cited by in Crossref: 415] [Cited by in F6Publishing: 426] [Article Influence: 138.3] [Reference Citation Analysis]
135 Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna) 2019;126:933-95. [PMID: 31214855 DOI: 10.1007/s00702-019-02028-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
136 Vatter S, Stanmore E, Clare L, Mcdonald KR, Mccormick SA, Leroi I. Care Burden and Mental Ill Health in Spouses of People With Parkinson Disease Dementia and Lewy Body Dementia. J Geriatr Psychiatry Neurol 2020;33:3-14. [DOI: 10.1177/0891988719853043] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
137 Canerina-Amaro A, Pereda D, Diaz M, Rodriguez-Barreto D, Casañas-Sánchez V, Heffer M, Garcia-Esparcia P, Ferrer I, Puertas-Avendaño R, Marin R. Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease. Front Neurosci 2019;13:382. [PMID: 31068782 DOI: 10.3389/fnins.2019.00382] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
138 Candelise N, Schmitz M, Llorens F, Villar-Piqué A, Cramm M, Thom T, da Silva Correia SM, da Cunha JEG, Möbius W, Outeiro TF, Álvarez VG, Banchelli M, D'Andrea C, de Angelis M, Zafar S, Rabano A, Matteini P, Zerr I. Seeding variability of different alpha synuclein strains in synucleinopathies. Ann Neurol 2019;85:691-703. [PMID: 30805957 DOI: 10.1002/ana.25446] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 22.3] [Reference Citation Analysis]
139 Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Aarsland D, Nobili F. Metabolic patterns across core features in dementia with lewy bodies. Ann Neurol 2019;85:715-25. [PMID: 30805951 DOI: 10.1002/ana.25453] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
140 Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: A Perfect Storm. Am J Geriatr Psychiatry 2019;27:998-1018. [PMID: 31006550 DOI: 10.1016/j.jagp.2019.03.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 17.3] [Reference Citation Analysis]
141 Olfati N, Shoeibi A, Litvan I. Progress in the treatment of Parkinson-Plus syndromes. Parkinsonism & Related Disorders 2019;59:101-10. [DOI: 10.1016/j.parkreldis.2018.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
142 Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor JP, Thomas A, Attems J, McKeith I. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener 2019;14:5. [PMID: 30665447 DOI: 10.1186/s13024-019-0306-8] [Cited by in Crossref: 125] [Cited by in F6Publishing: 129] [Article Influence: 41.7] [Reference Citation Analysis]
143 Tan SH, Karri V, Tay NWR, Chang KH, Ah HY, Ng PQ, Ho HS, Keh HW, Candasamy M. Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease. Biomed Pharmacother 2019;111:765-77. [PMID: 30612001 DOI: 10.1016/j.biopha.2018.12.101] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 17.3] [Reference Citation Analysis]
144 Morgante F, Valente EM. LRP10: A novel disease gene bridging Parkinson's disease and dementia with Lewy body. Mov Disord 2019;34:47. [PMID: 30597596 DOI: 10.1002/mds.27593] [Reference Citation Analysis]
145 Yoo HS, Chung SJ, Lee PH, Sohn YH, Kang SY. The Influence of Body Mass Index at Diagnosis on Cognitive Decline in Parkinson's Disease. J Clin Neurol 2019;15:517-26. [PMID: 31591841 DOI: 10.3988/jcn.2019.15.4.517] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
146 Laskowska E, Kuczyńska-Wiśnik D, Lipińska B. Proteomic analysis of protein homeostasis and aggregation. J Proteomics 2019;198:98-112. [PMID: 30529741 DOI: 10.1016/j.jprot.2018.12.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
147 Cousins O, Yousaf T, Wilson H, Pagano G, Politis M. Molecular Imaging of Dementia With Lewy Bodies. Int Rev Neurobiol 2019;144:59-93. [PMID: 30638457 DOI: 10.1016/bs.irn.2018.10.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
148 Lim EW, Aarsland D, Ffytche D, Taddei RN, van Wamelen DJ, Wan YM, Tan EK, Ray Chaudhuri K; Kings Parcog groupMDS Nonmotor study group. Amyloid-β and Parkinson's disease. J Neurol 2019;266:2605-19. [PMID: 30377818 DOI: 10.1007/s00415-018-9100-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
149 Hammes J, Drzezga A, van Eimeren T. The Role of Tau Imaging in Parkinsonian Disorders. Curr Neurol Neurosci Rep 2018;18:86. [PMID: 30293094 DOI: 10.1007/s11910-018-0898-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
150 Strand BH, Knapskog AB, Persson K, Edwin TH, Amland R, Mjørud M, Bjertness E, Engedal K, Selbæk G. Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway. PLoS One 2018;13:e0204436. [PMID: 30240425 DOI: 10.1371/journal.pone.0204436] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
151 Palermo G, Ceravolo R, Bonuccelli U. Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opin Pharmacother 2018;19:1643-53. [PMID: 30212224 DOI: 10.1080/14656566.2018.1519548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
152 Mouton A, Blanc F, Gros A, Manera V, Fabre R, Sauleau E, Gomez-Luporsi I, Tifratene K, Friedman L, Thümmler S, Pradier C, Robert PH, David R. Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study. Alzheimers Res Ther 2018;10:92. [PMID: 30208961 DOI: 10.1186/s13195-018-0417-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
153 Santiago JA, Bottero V, Potashkin JA. Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program. Front Aging Neurosci 2018;10:157. [PMID: 29896099 DOI: 10.3389/fnagi.2018.00157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
154 Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018;125:615-650. [PMID: 29222591 DOI: 10.1007/s00702-017-1821-9] [Cited by in Crossref: 128] [Cited by in F6Publishing: 144] [Article Influence: 25.6] [Reference Citation Analysis]
155 Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors T, Navarro PP, Castaño-díez D, Schweighauser G, Graff-meyer A, Goldie KN, Sütterlin R, Huisman E, Ingrassia A, de Gier Y, Rozemuller AJ, Wang J, De Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Großerüschkamp F, Niedieker D, El-mashtoly SF, Quadri M, van Ijcken WF, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, van de Berg WDJ, Lauer ME. Lewy pathology in Parkinson’s disease consists of a crowded organellar, membranous medley.. [DOI: 10.1101/137976] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]